Business combinations - Gain on bargain purchase (Details) - TCR2 Therapeutics $ / shares in Units, $ in Thousands |
Jun. 01, 2023
USD ($)
|
May 31, 2023
$ / shares
|
Mar. 06, 2023
$ / shares
|
|---|---|---|---|
| Merger with TCR2 Therapeutics Inc. | |||
| Purchase consideration | $ (61,726) | ||
| Net assets acquired and liabilities assumed | 83,775 | ||
| Gain on bargain purchase | $ 22,049 | ||
| Ratio for issuance of Company's ADSs for each TCR2 stock acquired | 1.5117 | ||
| Closing price of Company's ADS | $ / shares | $ 1.02 | $ 1.32 |
| X | ||||||||||
- Definition Ratio for issuance of Company's ADSs for each stock of the acquiree, acquired by the company under a business combination transaction. No definition available.
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition In a business combination in which the amount of net identifiable assets acquired and liabilities assumed exceeds the aggregate consideration transferred or to be transferred (as defined), this element represents the amount of gain recognized by the entity. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Price of a single share of a number of saleable stocks of a company. No definition available.
|
| X | ||||||||||
- Details
|